Q&A With Chesapeake Regional Healthcare

Posted by Tru-D SmartUVC 04.19.17

Chesapeake Regional Healthcare was one of the nine hospitals that participated in the CDC-funded, $2M Benefits of Enhanced Terminal Room-Disinfection (BETR-D) randomized clinical trial on UV disinfection. The study was conducted from 2012-2014 throughout the Duke Infection Control Outreach Network, and, during that time, CRH saw a 12 percent reduction in its C. diff rates. After participating in the study and seeing significant results, Chesapeake has invested in Tru-D SmartUVC to help with its infection rates.

 

Tru-D recently spoke with Tiffany Silmon, Director, Infection Prevention of Chesapeake Regional Healthcare, to discuss the study and how it has impacted the hospital’s infection prevention rates and protocols.

How are your cleaning protocols different now from during the study period? 

Right now, we are utilizing the same protocols as the study in terms of products. However, unlike the study, we do not used the pH pens to check if the surfaces were cleaned with the appropriate product (i.e.,  bleach for C. diff, quaternary ammonium for bacteria). This is because we are in the process of changing to single peracetic acid based product with sporicidal properties.

Is your team excited to have Tru-D back on staff?

Yes, they are!  The study afforded us the opportunity to really emphasize how enhanced terminal cleaning of the patient’s environment reduces the risk of infection.

In terms of the study, how was the integration of Tru-D with regard to room turnover time and workflow?

We had to work closely with the nursing supervisors who control our bed flow.  Like any new process we had to work out the kinks, mainly in communication, but we were able to successfully move forward.  In terms of increase in room turnover time, it didn’t add a significant amount of time to the room turnover. For those critical care rooms that were needed right away, we implemented a process that allowed for the machines to run at least 20 minutes.  It worked out well.

Where do you plan on using the four Tru-D units—only in isolation cases or also in operating suites and other areas? 

One of the Tru-D units will be dedicated to our OR suite. The other three will be utilized facility-wide. Initially, we will be prioritizing C. diff cases and isolation rooms in our critical care areas, but the long-term goal is to incorporate Tru-D as part of the terminal cleaning process for every room.

How do you plan to track your success with Tru-D going forward and how can we help?

C. diff infection is a focus for our organization, so decreases in these hospital onset rates will be a key outcome.  We also want to track usage to ensure we are taking advantage of all opportunities to use our Tru-D units.

We know the study was a success overall, but can you share how Chesapeake fared during the study. Did you see drops in infection rates that were notable?

We did experience a significant decrease in both infection and colonization rates with all multidrug-resistant organisms (MDROs) and about a 12 % decrease in C. diff infections  during the arms of the study that included Tru D units and bleach.  The successful outcome we experienced from combining of UV technology and a sporicidal agent was one of the key reasons for moving to a single product for manual cleaning.

To read more about the study, click here.

Posted 04.19.17
  • Share

Never miss the latest in UV news.
Subscribe to UVC360 today.

Sign Up »